Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2016

View Archived Issues

Asceneuron discloses glycosidase inhibitors

PharmaResearch Products and Lipopeptide establish strategic collaboration in wound care

Scientists report miRNAs that may be associated with mBCC

PsiOxus Therapeutics begins combination treatment in OCTAVE study

Gilead Sciences patents compounds to treat HIV

Han Wha Pharma and Yang Ji Chemical disclose JAK inhibitors

Prexton Therapeutics introduces mGlu4 receptor PAMs

Bristol-Myers Squibb describes HIV integrase inhibitors

University of Dayton reports antineoplastic and antibacterial compounds

AnaptysBio starts dosing in first-in-human phase I trial of ANB-020

Senhwa Biosciences enters agreement with CCTG for phase I/II study of CX-5461

Vericel releases topline results from phase IIb study of ixmyelocel-T

Phase III data show sarilumab superior to adalimumab in patients with active rheumatoid arthritis

FDA accepts for review Enbrel sBLA for pediatric chronic severe plaque psoriasis

Scancell and Karolinska Institutet collaborate to explore role of citrullination in cancer

Double-blind trial evaluates mexiletine in sporadic amyotrophic lateral sclerosis

SRI International awarded National Cancer Institute contract to develop cancer treatments

Bioresorbable sensors may enable wireless data collection in deep tissue and body cavities

Lundbeck initiates phase III program of Lu-AF-35700 for treatment-resistant schizophrenia

Enrollment under way in phase III trial of elafibranor for NASH

Novartis submits sBLA for ofatumumab with fludarabine and cyclophosphamide for relapsed CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...